SELLAS Announces FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia Read more
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology Read more
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe Read more
AtomVie Global Radiopharma and Radiopharm Theranostics Join Forces to Develop 177Lu-BetaBart Radioantibody for Solid Tumor Treatment Read more
Exelixis and Merck Partner to Advance Zanzalintinib Trials with KEYTRUDA in Head and Neck Cancer and WELIREG in Renal Cell Carcinoma Read more
Enhertu Gains Approval in China as First HER2-Directed Therapy for HER2-Mutant Metastatic Non-Small Cell Lung Cancer Read more
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation Read more